Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that publicly reports on its performance and activities through regular news releases and investor communications. The company describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings, and it is headquartered in San Clemente, California.
The ICUI news feed on Stock Titan aggregates company announcements that cover a range of topics important to investors and industry observers. These include quarterly earnings results, updates to fiscal year guidance, and details on product line revenues across Consumables, Infusion Systems and Vital Care. ICU Medical’s earnings releases also discuss items such as gross profit, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share, and commentary from management on recent performance.
In addition to financial results, ICU Medical issues news about corporate and strategic developments. Recent disclosures include the completion of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. focused on IV solutions manufacturing and innovation in North America. The company also announces its participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and events hosted by Piper Sandler, Wells Fargo and Morgan Stanley.
Through these updates, readers can follow how ICU Medical communicates its business progress, financial outlook and strategic initiatives. The ICUI news page on Stock Titan provides a centralized view of press releases related to earnings, guidance, joint ventures, conference appearances and other material events referenced in the company’s SEC filings. Investors and researchers can use this stream of information to monitor developments in ICU Medical’s infusion systems, consumables, vital care product lines and broader corporate activities over time.
ICU Medical (Nasdaq: ICUI) announced management will participate in three investor conferences in March–April 2026: Raymond James on March 2, 2026 (presentation at 11:15 a.m. PT), KeyBanc Healthcare Forum on March 18, 2026 (fireside chat at 10:30 a.m. PT), and Needham on April 13, 2026 (presentation at 7:15 a.m. PT).
A live audio webcast and archived replays will be available via the company investor website at https://ir.icumed.com.
ICU Medical (Nasdaq:ICUI) reported Q4 2025 revenue of $540.7M versus $629.8M a year earlier; full-year 2025 revenue was $2,231.3M versus $2,382.0M. GAAP Q4 gross margin improved to 38% from 36% and GAAP Q4 net loss narrowed to $(15.7)M.
Adjusted Q4 EPS was $1.91 and adjusted EBITDA was $98.2M. For FY 2026 the company guides GAAP net income of $26M–$44M, adjusted EBITDA $400M–$430M, and adjusted EPS $7.75–$8.45. Vital Care declined after the May 1, 2025 IV Solutions disposal.
ICU Medical (Nasdaq: ICUI) announced the timing for its fourth quarter 2025 earnings release and conference call. Results will be released on Thursday, February 19, 2026 at ~4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.
The call is accessible by phone (800-274-8461, conference ID “ICUMED”) and by webcast via the company website under Investors; a replay will be available.
ICU Medical (Nasdaq: ICUI) announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12–15, 2026.
The live presentation is scheduled for Wednesday, January 14, 2026 at 1:30 p.m. PT (4:30 p.m. ET), with management also holding one-on-one meetings that day. The presentation will be webcast live and available for replay on the company investor website under the Events or Investor Calendar section.
ICU Medical (Nasdaq: ICUI) said company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
The fireside chat is scheduled for Thursday, December 4, 2025 at 10:00 a.m. PT (1:00 p.m. ET); management will also hold one-on-one meetings that day. The session will be webcast live and available for replay via the company website Investor Events Calendar at http://www.icumed.com.
ICU Medical (Nasdaq:ICUI) reported third quarter 2025 results and raised FY2025 guidance on Nov 6, 2025. Q3 revenue was $537.0M versus $589.1M year-ago; GAAP gross profit was $200.9M and gross margin improved to 37% from 35%.
GAAP net loss narrowed to $(3.4)M (loss of $(0.14) per diluted share); adjusted diluted EPS was $2.03 (prior year $1.59) and adjusted EBITDA was $105.9M (prior year $94.8M). Company updated FY2025 guidance: GAAP net loss range to $(8)M–$0M, adjusted EBITDA to $395M–$405M, and diluted EPS to $7.35–$7.65.
ICU Medical (Nasdaq: ICUI) will release its third quarter 2025 results on Thursday, November 6, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT). The company will host a conference call to discuss results on November 6, 2025 at 4:30 p.m. ET (1:30 p.m. PT).
Investors can join by phone at (800) 267-6316 with conference ID “ICUMED”, or listen via webcast on the company website under the Investors > Webcast section. A replay of the webcast will be available after the call.
ICU Medical (Nasdaq:ICUI), a leader in innovative medical products, has announced its participation in two upcoming investor conferences in September 2025. The company will participate in the Wells Fargo 2025 Healthcare Conference on September 4 in Boston, with a fireside chat scheduled for 1:30 p.m. PT. Additionally, management will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 in New York, with a presentation at 5:30 a.m. PT.
Both events will feature management participating in one-on-one meetings and fireside chats, which will be webcast live and archived on ICU Medical's investor relations website.
ICU Medical (Nasdaq:ICUI) reported its Q2 2025 financial results with revenue of $548.9 million, down from $596.5 million in Q2 2024. The company showed improved profitability with GAAP net income of $35.3 million ($1.43 per diluted share), compared to a net loss of $(21.4) million in Q2 2024.
Key metrics include improved GAAP gross margin of 38% (up from 35%), adjusted diluted EPS of $2.10 (up from $1.56), and adjusted EBITDA of $100.3 million (up from $91.3 million). The company updated its FY2025 guidance, narrowing adjusted EBITDA expectations to $380-390 million and adjusted EPS to $6.85-7.15.
ICU Medical (Nasdaq: ICUI), a leading medical products manufacturer, has scheduled its second quarter 2025 earnings release and conference call. The company will release Q2 2025 results on Thursday, August 7, 2025, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET.
Investors can access the call via phone at (800) 267-6316 using conference ID "ICUMED" or through a webcast available on the company's website. The webcast will also be available for replay through ICU Medical's investor relations section at www.icumed.com.